A Study of CS1003 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
effect of a new drug known as CS1003 in patients with advanced tumors.